Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

医学 来那度胺 达拉图穆马 多发性骨髓瘤 地塞米松 临床终点 硼替佐米 移植 自体干细胞移植 内科学 外科 临床试验
作者
Peter M. Voorhees,Douglas W. Sborov,Jacob P. Laubach,Jonathan L. Kaufman,Brandi Reeves,Cesar Rodriguez,Ajai Chari,Rebecca Silbermann,Luciano J. Costa,Larry D. Anderson,Nitya Nathwani,Nina Shah,Naresh Bumma,Yvonne A. Efebera,Sarah A. Holstein,Caitlin Costello,Andrzej Jakubowiak,Tanya M. Wildes,Robert Z. Orlowski,Kenneth H. Shain
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:10 (10): e825-e837 被引量:104
标识
DOI:10.1016/s2352-3026(23)00217-x
摘要

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (D-RVd) in the GRIFFIN study improved the stringent complete response rate by the end of consolidation in transplantation-eligible patients with newly diagnosed multiple myeloma. Here, we report the findings of the predefined final analysis.GRIFFIN was an open-label, randomised, active-controlled, phase 2 trial done in 35 research centres in the USA. Patients had newly diagnosed multiple myeloma with measurable disease by M protein or free light chain, were aged 18-70 years, had an ECOG performance score of 0-2, and were eligible for autologous haematopoietic stem-cell transplantation (HSCT). Patients were randomly assigned (1:1) to four D-RVd or RVd induction cycles, autologous HSCT, two D-RVd or RVd consolidation cycles, and lenalidomide with or without daratumumab maintenance therapy for 2 years. Patients received 21-day cycles of oral lenalidomide (25 mg on days 1-14), subcutaneous bortezomib (1·3 mg/m2 on days 1, 4, 8, and 11), oral dexamethasone (40 mg weekly) with or without intravenous daratumumab (16 mg/kg weekly, cycles 1-4; day 1, cycles 5-6). Maintenance therapy (28-day cycles) was oral lenalidomide (10 mg on days 1-21) with or without daratumumab (16 mg/kg intravenously every 4 or 8 weeks, or 1800 mg subcutaneously monthly). Patients could continue lenalidomide maintenance after study treatment completion. The primary endpoint was stringent complete response rate by the end of consolidation in the response-evaluable population, and has already been reported. Here we report updated stringent complete response rates and secondary outcomes including progression-free survival and overall survival. The trial is registered with ClinicalTrials.gov (NCT02874742) and ended on April 8, 2022.Between Dec 20, 2016, and April 10, 2018, 104 patients were randomly assigned to the D-RVd group and 103 were randomly assigned to the RVd group; most patients were White (85 [82%] in the D-RVd group and 76 [74%] in the RVd group) and male (58 [56%] in the D-RVd group and 60 [58%] in the RVd group). At a median follow-up of 49·6 months (IQR 47·4-52·1), D-RVd improved rates of stringent complete response (67 [67%] of 100] vs 47 [48%] of 98]; odds ratio 2·18 [95% CI 1·22-3·89], p=0·0079), and 4-year progression-free survival was 87·2% (95% CI 77·9-92·8) for D-RVd versus 70·0% (95% CI 55·9-80·3) for RVd, with a hazard ratio (HR) of 0·45 (95% CI 0·21-0·95, p=0·032) for risk of disease progression or death with D-RVd. Median overall survival was not reached for either group (HR 0·90 [95% CI 0·31-2·56], p=0·84). The most common grade 3-4 treatment-emergent adverse events in the D-RVd versus RVd groups were neutropenia (46 [46%] of 99 vs 23 [23%] of 102), lymphopenia (23 [23%] vs 23 [23%]), leukopenia (17 [17%] vs eight [8%]), thrombocytopenia (16 [16%] vs nine [9%]), pneumonia (12 [12%] vs 14 [14%]), and hypophosphataemia (ten [10%] vs 11 [11%]). Serious treatment-emergent adverse events occurred in 46 (46%) of 99 patients in the D-RVd group and in 53 (52%) of 102 patients in the RVd group. One patient in each treatment group reported a treatment-emergent adverse event that resulted in death (bronchopneumonia in the D-RVd group; cause unknown in the RVd group); neither was related to study treatment. No new safety concerns occurred with maintenance therapy.Addition of daratumumab to RVd improved the depth of response and progression-free survival in transplantation-eligible patients with newly diagnosed multiple myeloma. These results justify further evaluation in phase 3 studies.Janssen Oncology.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
坦率的匪举报111求助涉嫌违规
刚刚
长情的千风完成签到,获得积分10
刚刚
刚刚
woshiwuziq完成签到 ,获得积分10
1秒前
anna1992发布了新的文献求助10
2秒前
YY完成签到,获得积分10
2秒前
符宇新发布了新的文献求助10
2秒前
iNk应助kk采纳,获得10
3秒前
小马甲应助有机分子笼采纳,获得10
3秒前
3秒前
3秒前
张文静发布了新的文献求助30
3秒前
沉默的小天鹅应助xiaose采纳,获得10
4秒前
章宇完成签到,获得积分10
4秒前
充电宝应助123采纳,获得10
5秒前
想喝冰美完成签到,获得积分10
5秒前
bkagyin应助小海采纳,获得10
5秒前
帅气凝云完成签到,获得积分10
5秒前
LUKW给嘟嘟喂嘟嘟的求助进行了留言
5秒前
5秒前
清新的寄风完成签到 ,获得积分10
6秒前
难过的一一完成签到,获得积分10
6秒前
Jasper应助Ancient采纳,获得10
6秒前
孙刚发布了新的文献求助10
6秒前
英勇皮卡丘完成签到,获得积分10
7秒前
Deny发布了新的文献求助10
7秒前
7秒前
7秒前
7秒前
xinanan完成签到,获得积分10
7秒前
荔枝多酚完成签到,获得积分10
8秒前
Coraline发布了新的文献求助10
8秒前
坦率的匪举报金闪闪求助涉嫌违规
8秒前
GGGGGG果果发布了新的文献求助10
8秒前
8秒前
9秒前
9秒前
64658应助Ruby采纳,获得10
9秒前
kiki完成签到 ,获得积分10
10秒前
小二郎应助fafamimireredo采纳,获得10
10秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Handbook of Marine Craft Hydrodynamics and Motion Control, 2nd Edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3987078
求助须知:如何正确求助?哪些是违规求助? 3529488
关于积分的说明 11245360
捐赠科研通 3267987
什么是DOI,文献DOI怎么找? 1804013
邀请新用户注册赠送积分活动 881270
科研通“疑难数据库(出版商)”最低求助积分说明 808650